Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs)
$102.40
pos +1.94
+1.93%
Today's Range: 99.56 - 102.74 | GILD Avg Daily Volume: 14,968,800
Last Update: 12/17/14 - 4:00 PM EST
Volume: 13,542,580
YTD Performance: 33.77%
Open: $100.47
Previous Close: $100.46
52 Week Range: $63.50 - $116.83
Oustanding Shares: 1,508,664,333
Market Cap: 155,633,812,592
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 13 12 12 12
Moderate Buy 2 2 2 1
Hold 3 3 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.44 1.47 1.38 1.33
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 18.29
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
18.29 18.20 24.99
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-4.10% 40.66% 440.69%
GROWTH 12 Mo 3 Yr CAGR
Revenue 15.50 0.41 0.12
Net Income 18.80 0.06 0.02
EPS 10.80 0.18 0.06
Earnings for GILD:
EBITDA 4.87B
Revenue 11.20B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $2.36 $3.49 $7.91 $11.88
Number of Analysts 1 1 1 1
High Estimate $2.36 $3.49 $7.91 $11.88
Low Estimate $2.36 $3.49 $7.91 $11.88
Prior Year $0.52 $1.44 $1.92 $7.91
Growth Rate (Year over Year) 353.85% 142.36% 311.98% 50.19%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Doug Kass

 | Dec 12, 2014 | 2:38 PM EST
But looks like the second-worst weekly loss of the year.
By

Bret Jensen

 | Dec 11, 2014 | 11:30 AM EST

I would pick up some large caps on any significant dips.

By

Bret Jensen

 | Dec 8, 2014 | 10:00 AM EST

Forget the bears. I'd buy on a dip.

By

Jim Cramer

 | Dec 3, 2014 | 3:59 PM EST

An immense market rotation is happening.

updatePiper Healthcare Conf.

Dec 3, 2014 | 7:25 AM EST

Piper Jaffray Healthcare Conference (Day 2 of 2) - 12/02/14 - 12/03/14 New York City,

By

Bret Jensen

 | Nov 28, 2014 | 10:00 AM EST

The market seems to be severely discounting DynaVax's chances of approval for its hep-B treatment.

By

David Katz

 | Nov 21, 2014 | 9:30 AM EST

Its prospects exploded with a breakthrough drug.

By

Carolyn Boroden

 | Nov 16, 2014 | 6:00 PM EST

Gilead and YY are poised for potential climbs.

By

Doug Kass

 | Nov 14, 2014 | 10:20 AM EST
On Hep C data.
By

Jim Cramer

 | Nov 11, 2014 | 4:13 PM EST

Investors are seeing growth today in three areas.

AAPL needs to clear this hurdle IF this last low is any good!!

...
The Fed didn't raise interest rates, but the market did via lower bond and note prices. Th...
WHR has regained all the of the ground lost over the last nine sessions during today's...
Just to let you know, the three dissents come from governors who will not be voting member...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.